EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteome Profiling of Cerebrospinal Fluid and Machine Learning Reveal Protein Classifiers of Two Forms of Alzheimer’s Disease Characterized by Increased or Not Altered Levels of Tau

Elisabetta Scalia, Matteo Calligaris, Margot Lo Pinto, Salvatore Castelbuono, Matilda Iemmolo, Vincenzina Lo Re, Giulia Bivona, Tommaso Piccoli, Giulio Ghersi, Simone Dario Scilabra

Molecular & Cellular Proteomics · 2025

DOI: 10.1016/j.mcpro.2025.101025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2025. Verfasst von Elisabetta Scalia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Proteomics Group of Ri.MED Foundation, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), P…. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Machine Learning, Proteomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder that presents with heterogeneous clinical and pathological features, necessitating improved biomarkers for accurate diagnosis and patient stratification. In this study, we applied a data-independent acquisition-based proteomics workflow to cerebrospinal fluid (CSF) samples from 138 individuals, including AD patients with high (Aβ+/tau+) or normal (Aβ+/tau-) CSF tau levels, and non-AD controls. Analysis using an Astral mass spectrometer enabled unprecedented proteome depth, identifying 2661 proteins with high data completeness. Comparative proteomic profiling revealed distinct protein signatures for Aβ+/tau+ and Aβ+/tau- subtypes. These findings were validated using an independent internal cohort and further corroborated with publicly available datasets from larger external AD cohorts, demonstrating the robustness and reproducibility of our results. Using machine learning, we identified a panel of 15 protein classifiers that accurately distinguished the two AD subtypes and controls across datasets. Notably, several of these proteins were elevated in the preclinical stage, underscoring their potential utility for early diagnosis and stratification. Together, our results demonstrate the power of data-independent acquisition proteomics on the Astral platform, combined with machine learning, to uncover subtype-specific biomarkers of AD and support the development of personalized diagnostic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasetau ProteinsMachine LearningProteomicsProteomeHumansFemaleMaleBiomarkersAgedAmyloid beta-PeptidesMiddle AgedAged, 80 and overCase-Control StudiesReproducibility of Results

Stichwörter der Autor:innen

Alzheimer’s diseasecerebrospinal fluiddata-independent acquisition (DIA) proteomicsmachine learningprotein classifiers

Substanzen

tau ProteinsBiomarkersProteomeAmyloid beta-Peptides

Autor:innen und Institutionen

  • Proteomics Group of Ri.MED Foundation, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy; Department of Biological, Chemical and Pharmaceutical S…
  • Department of Medical Area (DAME), Università degli studi di Udine, Udine, Italy.
  • Proteomics Group of Ri.MED Foundation, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.
  • Research Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione), Palermo, Italy; Department of Engineering, University of Palermo, Palermo, Italy.
  • Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy.
  • Neurology Service, Department of Diagnostic and Therapeutic Services, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), University of Pittsburgh Medical Center (UPMC), Palermo, Ita…

Förderung

  • European Commission

Zitieren

APA

Scalia, E., Calligaris, M., Lo Pinto, M., Castelbuono, S., Iemmolo, M., Lo Re, V., Bivona, G., Piccoli, T., Ghersi, G., & Scilabra, S. D. (2025). Proteome Profiling of Cerebrospinal Fluid and Machine Learning Reveal Protein Classifiers of Two Forms of Alzheimer’s Disease Characterized by Increased or Not Altered Levels of Tau. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2025.101025

Vancouver

Scalia E, Calligaris M, Lo Pinto M, Castelbuono S, Iemmolo M, Lo Re V, et al. Proteome Profiling of Cerebrospinal Fluid and Machine Learning Reveal Protein Classifiers of Two Forms of Alzheimer’s Disease Characterized by Increased or Not Altered Levels of Tau. Molecular & Cellular Proteomics. 2025. doi:10.1016/j.mcpro.2025.101025

BibTeX
@article{Scalia2025,
  author = {Scalia, Elisabetta and Calligaris, Matteo and Lo Pinto, Margot and Castelbuono, Salvatore and Iemmolo, Matilda and Lo Re, Vincenzina and Bivona, Giulia and Piccoli, Tommaso and Ghersi, Giulio and Scilabra, Simone Dario},
  title = {Proteome Profiling of Cerebrospinal Fluid and Machine Learning Reveal Protein Classifiers of Two Forms of Alzheimer’s Disease Characterized by Increased or Not Altered Levels of Tau},
  journal = {Molecular & Cellular Proteomics},
  year = {2025},
  doi = {10.1016/j.mcpro.2025.101025}
}
Kostenlos starten →